Lifeward Ltd. presented new data at the ASIA 2026 conference showing that the ReWalk powered exoskeleton has a very low fracture rate, with only 3% lifetime prevalence globally since 2013 and just 0.3% in the last six years. Notably, no fractures were reported among 97 German users since 2018, despite diverse patient profiles. These findings highlight significant safety improvements due to better device design and training, supporting wider adoption of ReWalk for spinal cord injury rehabilitation. The data reinforce ReWalk's role as a safe and effective mobility aid for people with spinal cord injuries.
ISS has secured a seven-year contract with West Sussex County Council to deliver around 25,000 nutritious school meals daily to primary schools starting Q3 2026. The contract, valued at about DKK 100 million annually, emphasizes inclusivity and high ...
Roche has introduced the Liver Disease Panel, the first comprehensive set of certified algorithms designed to improve the detection and management of chronic liver disease (CLD). This panel includes LiverPRO, an algorithm that uses routine blood mark...
TGS ASA has secured a large 4D streamer contract offshore Angola, set to begin data acquisition in early July 2026 and last about eight months. This contract strengthens TGS's strategic presence in Africa and ensures vessel utilization into early 202...
argenx, a global immunology company focused on autoimmune diseases, announced its management team will present at two key investor conferences in June: the William Blair 46th Annual Growth Stock Conference and the Goldman Sachs 47th Annual Global Hea...
Capgemini unveiled its 2028 strategic plan focusing on leveraging AI agent technology to drive business transformation for large enterprises. The company aims for a 5.5% to 7.5% annual revenue growth from 2025 to 2028, with about 2 points from merger...
